Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

Science Daily - 8 Oct 2016 19:48
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results.
Full Article at Science Daily

More Science News
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard